Evidence map›Paper›PMID 41826281›Full record

Trial reportNature communications2026

Cadonilimab plus chemotherapy with or without bevacizumab as first-line treatment for advanced cervical cancer: subgroup analyses from the COMPASSION-16 phase 3 trial.

Yang Sun, Hongying Yang, Jing Wang, Hanmei Lou, Dan Li, Ke Wang, Hui Zhang, Tao Wu, Yuzhi Li, Chunyan Wang and 55 more

Abstract readClinical Trial, Phase IIIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

65 authors.

Yang Sun *Department of Gynecology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.ORCID http://orcid.org/0000-0002-1587-9797
Hongying Yang *Gynecology Department, Yunnan Cancer Hospital, Kunming, China.
Jing WangGynecologic Oncology Department, Hunan Cancer Hospital, and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
Hanmei LouGynecologic Radiation Department, Zhejiang Cancer Hospital, Hangzhou, China.
Dan LiOncology Department, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
Ke WangGynecologic Oncology Department, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Hui ZhangGynecology Department, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Tao WuOncology Department, Changde Hospital, Xiangya School of Medicine, Central South University, Changde, China.
Yuzhi LiGynecologic Oncology Department, The First Affiliated Hospital of Bengbu Medical University, Bengbu, China.
Chunyan WangGynecology Department, Liaoning Cancer Hospital and Institute, Shenyang, China.
Guiling LiGynecologic Oncology Department, Union Hospital Affiliated to Tongji Medical College, Wuhan, China.
Yifeng WangObstetrics and Gynaecology Department, Zhujiang Hospital of Southern Medical University, Guangzhou, China.
Dapeng LiUterine Tumor Ward I, Cancer Hospital of Shandong First Medical University, Jinan, China.
Ying TangGynecologic Oncology Department, Affiliated Cancer Hospital of Chongqing University, Chongqing, China.
Mei PanGynecology Department, Jiangxi Maternal and Child Health Hospital, Nanchang, China.
Hongyi CaiRadiotherapy Department, Gansu Provincial Hospital, Lanzhou, China.
Weihu WangRadiotherapy Department, Beijing Cancer Hospital, Beijing, China.ORCID http://orcid.org/0000-0003-4969-398X
Bing YangGynecology Department, Affiliated Hospital of Zunyi Medical University, Zunyi, China.
Hua QianGynecology Department, Taizhou People's Hospital Affiliated to Nanjing Medical University, Taizhou, China.
Qiuhong TianOncology Department, The First Affiliated Hospital of Nanchang University, Nanchang, China.
Desheng YaoGynecology Department, Guangxi Medical University Cancer Hospital & Guangxi Cancer Institute, Nanning, China.
Ying ChengOncology Department, Jilin Cancer Hospital, Changchun, China.ORCID http://orcid.org/0000-0001-9908-597X
Bing WeiObstetrics and Gynecology Department, The Second Hospital of Anhui Medical University, Hefei, China.
Xiumin LiGynecology Ward 2, Linyi Cancer Hospital, Linyi, China.
Tao WangDepartment of Radiotherapy, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Min HaoObstetrics and Gynecology Department, Second Hospital of Shanxi Medical University, Taiyuan, China.
Xiaohong WangDepartment of Radiotherapy, The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China.
Tiejun WangDepartment of Radiotherapy, Second Hospital of Jilin University, Changchun, China.
Chang LiuGynecology Department, The First Hospital of Lanzhou University, Lanzhou, China.
Hong ZhuOncology Department, Xiangya Hospital Central South University, Changsha, China.
Lijing ZhuOncology Department, Nanjing Drum Tower hospital, Nanjing, China.
Xianling LiuOncology Department, The Second Xiangya Hospital, Central South University, Changsha, China.
Yunxia LiMedical Oncology Department, General Hospital of Ningxia Medical University, Yinchuan, China.
Lihong ChenGynecology Department, Shaanxi Provincial People's Hospital, Xi'an, China.
Qingshan LiOncology Department, Affiliated Hospital of Chengde Medical University, Chengde, China.
Xiaojian YanDepartment of Gynecology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Fei WangGynecology Department, Shandong Provincial Hospital, Jinan, China.
Hongbing CaiGynecologic Oncology Department, Zhongnan Hospital Affiliated to Wuhan University, Wuhan, China.
Yunyan ZhangGynecologic Radiotherapy Department, Affiliated Cancer Hospital of Harbin Medical University, Harbin, China.
Zhiqing LiangObstetrics and Gynecology Department, The First Affiliated Hospital of Army Military Medical University, Chongqing, China.
Funan LiuPhase I Clinical Trials Centre, The First Hospital of China Medical University, Shenyang, China.
Yi HuangGynecologic Oncology Department, Hubei Cancer Hospital, Wuhan, China.
Bairong XiaGynecology Department, Anhui Provincial Cancer Hospital, Hefei, China.
Pengpeng QuGynecologic Oncology Department, Tianjin Central Hospital of Gynecology Obstetrics, Tianjin, China.
Genhai ZhuGynecology Department, Hainan General Hospital, Haikou, China.
Youguo ChenGynecology Department, The First Affiliated Hospital of Soochow University, Suzhou, China.
Kun SongGynecology Department, Qilu Hospital of Shandong University, Jinan, China.ORCID http://orcid.org/0000-0001-6110-2770
Meili SunOncology Department, Jinan Central Hospital, Jinan, China.ORCID http://orcid.org/0000-0002-4914-6508
Zhengzheng ChenDepartment of Obstetrics and Gynecology, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, China.
Qiang ZhouOncology Department, Suining Central Hospital, Suining, China.
Lina HuGynecology Department, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Guzhalinuer AbuliziGynecology Department, Cancer Hospital Affiliated to Xinjiang Medical University, Urumqi, China.
Hongyan GuoObstetrics and Gynaecology Department, Peking University Third Hospital, Beijing, China.
Sihai LiaoGynecologic Oncology Department, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China.
Yijing YeDepartment of Radiation Therapy for Abdominal Tumor, Zhongshan City People's Hospital, Zhongshan, China.
Ping YanGynecology Department, Hebei General Hospital, Shijiazhuang, China.
Qiu TangDepartment of Radiation Oncology, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Guoping SunOncology Department, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Ting LiuAkeso Biopharma Inc., Zhongshan, China.
Dongmei LuAkeso Biopharma Inc., Zhongshan, China.
Mingxiu HuAkeso Biopharma Inc., Zhongshan, China.
Zhongmin M WangAkeso Biopharma Inc., Zhongshan, China.ORCID http://orcid.org/0000-0002-1683-5147
Baiyong LiAkeso Biopharma Inc., Zhongshan, China.
Michelle XiaAkeso Biopharma Inc., Zhongshan, China.
Xiaohua WuDepartment of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Shanghai, China. wu.xh@fudan.edu.cn.ORCID http://orcid.org/0000-0002-2271-2514

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The phase 3 COMPASSION-16 trial demonstrates significant progression-free survival (PFS) and overall survival (OS) benefits with cadonilimab plus standard therapy in patients with persistent, recurrent, or metastatic cervical cancer. This analysis aims to assess efficacy outcomes in patient subgroups of COMPASSION-16. The dual primary endpoints of COMPASSION-16 are PFS, assessed by the blinded independent central review (BICR) according to RECIST version 1.1, and OS. The secondary endpoint is objective response rate. In this subgroup analysis, the PFS, OS and objective response rate are evaluated in subgroups including bevacizumab use, prior concurrent chemoradiotherapy, PD-L1 combined positive score (CPS), metastatic disease at baseline, platinum use, and age. With median follow-up of 25.6 months, hazard ratios (HRs) for PFS favour cadonilimab group in all subgroups. Moreover, the addition of cadonilimab is also associated with prolonged overall survival. This subgroup analysis confirms that improvements in progression-free and overall survival are consistent with the primary results of the COMPASSION-16 study across diverse patient profiles.

Indexed as

Antibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBevacizumabUterine Cervical NeoplasmsAdultAgedFemaleHumansMiddle AgedProgression-Free SurvivalTreatment OutcomeAntibodies, Monoclonal, HumanizedBevacizumab

Identifiers

PMID41826281
PMCPMC13128965

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.